4-methoxy-2-(trifluoromethyl)benzo[d]thiazole | 354760-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 4-methoxy-2-(trifluoromethyl)benzo[d]thiazole
• 英文别名: 4-methoxy-2-trifluoromethylbenzothiazole；4-methoxy-2-(trifluoromethyl)-1,3-benzothiazole
• CAS: 354760-24-0
• 化学式: C₉H₆F₃NOS
• 分子量: 233.214
• InChiKey: PJAAHHGTTQCZOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  50.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-methoxy-2-(trifluoromethyl)benzo[d]thiazole 在 aluminum (III) chloride 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 硝基甲烷 为溶剂， 反应 12.5h， 生成 tert-butyl 4-(4-methoxy-2-(trifluoromethyl)benzo[d]thiazol-7-yl)-3-methyl-4-oxobutanoate
  参考文献：
  名称：

  Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure–activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity

  摘要：

  (-)-6-(7-甲氧基-2-三氟甲基嘌唑并[1,5-a]吡啶-4-基)-5-甲基-4,5-二氢-3-(2H)-吡啶嗪酮（KCA-1490）是一种 dual PDE3/4抑制剂，具有强大的联合支气管扩张和抗炎活性。对KCA-1490中嘌唑并[1,5-a]吡啶核心的潜在双环杂芳香族替换基团的调查已确定了4-甲氧基-2-(三氟甲基)苯并[d]噻唑-7-基和8-甲氧基-2-(三氟甲基)喹啉-5-基类似物作为 dual PDE3/4抑制剂，它们能有力地抑制组胺引起的支气管收缩，并在体内表现出抗炎活性。© 2012 Elsevier Ltd. 保留所有权利。

  DOI：

  10.1016/j.bmc.2012.01.033
• 作为产物：
  描述：

  2,2,2-trifluoro-N-(2-methoxyphenyl)ethanethioamide 在 palladium dichloride 作用下， 以 二甲基亚砜 为溶剂， 反应 3.0h， 以78%的产率得到4-methoxy-2-(trifluoromethyl)benzo[d]thiazole
  参考文献：
  名称：

  A General and Straightforward Method for the Synthesis of 2-Trifluoromethylbenzothiazoles

  摘要：

  An efficient one-pot method for the synthesis of 2-trifluoromethylbenzothiazoles by the treatment of trifluoromethylimidoyl chlorides with sodium hydrosulfide hydrate using PdCl(2) as the sole catalyst in DMSO is described. The reaction proceeds via thiolation/C H bond functionalization/C S bond formation in moderate to high yields with good functional group tolerance.

  DOI：

  10.1021/ol1006899

文献信息

• HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：Kohno Yasushi

  公开号：US20110178041A1

  公开（公告）日：2011-07-21

  Novel heterocyclic biaryl derivatives were disclosed which are useful as pharmaceutical agents and which exhibit a phosphodiesterase-inhibitory action. The heterocyclic biaryl derivatives are represented by the following general formula (1): wherein the Heterocycle 1 and the Heterocycle 2 are directly bonded together.

  揭示了一种新颖的杂环双芳基衍生物，可用作药物，并表现出磷酸二酯酶抑制作用。这些杂环双芳基衍生物由以下一般式（1）表示： 其中杂环1和杂环2直接连接在一起。
• PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：EP2168960A1

  公开（公告）日：2010-03-31

  It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.

  提供一种新颖的吡唑酮衍生物， represented by the following general formula (1)，该衍生物可用作药物，并具有磷酸二酯酶抑制作用： 其中 R1，R2：C1-6烷基；R3，R4：H，X，C1-6烷氧基；Z：O，S；A：AA，BB，其中AA代表 其中BB代表 其中R5：H，C1-6烷基；R6，R7：C1-6烷基。
• PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：EP2168959A1

  公开（公告）日：2010-03-31

  It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents: and BB represents: wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.

  提供一种新颖的吡啶并酮衍生物，其通式如下（1），可用作药物，并具有磷酸二酯酶抑制作用： 其中R1代表H或C1-6烷基，R2和R3各自代表H、X、C1-6烷氧基，Z代表O或S，A代表AA或BB，其中AA代表： 而BB代表： 其中R4代表H或C1-6烷基，R5和R6各自代表C1-6烷基。
• Benzothiazole compounds and their therapeutic use
  申请人：Darwin Discovery, Ltd.

  公开号：US06313116B1

  公开（公告）日：2001-11-06

  Compounds that are inhibitors of phosphodiesterase and have therapeutic utility, are of formula (i) wherein R1 is C3-6 cycoalkyl, or C1-3 alkyl optionally substituted with one or more fluorine atoms; R2 is C1-6 alkyl, C3-6 cycloalkyl, CF3, CH2CF3, C2F5 or NR4R5; R3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C) NR4R5 is a nitrogen-containing heterocyclic ring; R6 is C1-3 alkyl; and R7 and R8, which are the same or different, are each H, C1-3 alkyl, halogen, CF3 or CN, provided that both are not H; or a pharmaceutically-acceptable salt thereof

  具有治疗效用的磷酸二酯酶抑制剂化合物的化学式为（i），其中R1为C3-6环烷基，或C1-3烷基，可选地取代一个或多个氟原子；R2为C1-6烷基，C3-6环烷基，CF3，CH2 ，C2F5或NR4R5；R3为部分化学式（A），（B）或（C）的吡唑，咪唑或异唑基团，其中NR4R5是含氮的杂环环；R6为C1-3烷基；而R7和R8，相同或不同，分别为H，C1-3烷基，卤素， 或CN，前提是两者都不为H；或其药学上可接受的盐。
• ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：Kohno Yasushi

  公开号：US20110224250A1

  公开（公告）日：2011-09-15

  The present invention provides a novel isoquinoline derivative which is useful as a pharmaceutical agent having a phosphodiesterase inhibitory activity. The isoquinoline derivative of the present invention is represented by the following general formula (1):

  本发明提供了一种新型的异喹啉衍生物，其作为一种具有磷酸二酯酶抑制活性的药物剂使用。本发明的异喹啉衍生物由下列通式（1）表示：